Evaluating Rimegepant's safety in patients on migraine preventive therapy

Using Rimegepant 75 mg orally once daily for up to a year in adults on preventive migraine medications appears safe, offering a promising long-term treatment option for managing acute migraines.

The study aimed to assess the safety and tolerability of Rimegepant 75 mg, a CGRP receptor antagonist for acute migraines in individuals who are also taking preventive therapies for migraine.

In this long-term safety study, people experiencing 2 to 14 moderate or acute migraine attacks per month took Rimegepant 75 mg. It was taken either daily on a needed basis till 52 weeks or alternate day plus as required for 12 weeks. Preventive migraine medicines were permitted if the dosage was steady for at least 2 months prior to the first visit.

As found, 243 (13.5%) took a concomitant preventive therapy out of 1800 participants who took Rimegepant. Topiramate (26.3%) was the most common preventive therapy. Rimegepant usage was similar between the groups, with the mean (SD) number of doses per 4 weeks being 7.8 (4.5) for those on preventive medicines and 7.7 (4.7) for those not on preventives. The details of adverse events in those on preventive therapy and those without have been shown in the following Table 1:

Adverse events reported in at least 5% of participants in either cohort are (Table 2):

For up to a year, treating acute migraines with Rimegepant 75 mg oral was safe in adults also taking preventive migraine medications.